1. Bold 100: A Ruthenium-based Anticancer Therapeutic: Evolution of a Ruthenium-based Metallodrug.
- Author
-
Srividya, S. and Karvembu, R.
- Subjects
ANTINEOPLASTIC agents ,TESTICULAR cancer ,DRUG resistance ,CELL survival ,CISPLATIN - Abstract
It has been over half a century since Barnett Rosenberg discovered the cytotoxic action of cisplatin, the platinum-based (Pt-based) drug that has almost eradicated the cases of testicular cancers. Despite this advancement, cancer continues to be widespread, highlighting the imperative for the development of more effective drugs to combat this disease. Most malignancies are initially responsive to anticancer treatments, but cancer cells gain resistance with time. The GRP78 pathway, a key regulator of cellular stress and resistance, is the focus of BOLD-100, a first-in-class ruthenium-based (Ru-based) anticancer drug. This medication inhibits cell survival by preventing stress-induced overexpression of GRP78 in tumour cells, suppressing drug resistance, survival and proliferation. The following article dictates the evolution and the current scenario of the Ru-based drug BOLD-100. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF